What do analysts expect the price target to be for CHIMERIX INC (CMRX)?
11 analysts have analysed CMRX and the average price target is 8.71 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 8.54.
NASDAQ:CMRX • US16934W1062
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CHIMERIX INC (CMRX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-03-06 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-03-05 | Jefferies | Downgrade | Buy -> Hold |
| 2025-03-05 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-02-18 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-18 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-11-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-17 | Wedbush | Reiterate | Outperform -> Outperform |
| 2023-08-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-23 | Baird | Initiate | Outperform |
| 2023-05-05 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-03 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-09-07 | Capital One | Initiate | Overweight |
| 2022-05-17 | HC Wainwright & Co. | Maintains | Buy |
| 2021-12-22 | HC Wainwright & Co. | Maintains | Buy |
| 2021-11-22 | HC Wainwright & Co. | Maintains | Buy |
| 2021-06-07 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-06 | HC Wainwright & Co. | Maintains | Buy |
| 2021-04-29 | Maxim Group | Initiate | Buy |
| 2021-03-31 | Wedbush | Initiate | Outperform |
| 2021-03-31 | Jefferies | Initiate | Buy |
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 33.82M 1,608.08% | 324K -99.04% | 212K -34.57% | 5.334M 2,416.04% | 54.616M 923.92% | 133.37M 144.20% | 382.87M 187.07% | 600.96M 56.96% | 676.03M 12.49% | 500.22M -26.01% | 537.15M 7.38% | |
| EBITDA YoY % growth | -60.29M 33.26% | -92.974M -54.21% | -96.473M -3.76% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -60.39M 33.28% | -93.065M -54.11% | -96.567M -3.76% | -119.136M -23.37% | -79.783M 33.03% | -44.059M 44.78% | 179.85M 508.20% | 335.75M 86.68% | 384.29M 14.46% | 228.85M -40.45% | 300.75M 31.42% | |
| Operating Margin | -178.56% | -28,723.77% | -45,550.47% | -2,233.52% | -146.08% | -33.04% | 46.97% | 55.87% | 56.85% | 45.75% | 55.99% | |
| EPS YoY % growth | 1.96 194.23% | -0.92 -146.94% | -0.99 -7.61% | -0.85 13.80% | -0.88 -2.83% | -0.07 91.86% | 0.83 1,257.14% | 1.36 64.20% | 1.53 12.78% | 1.69 10.67% | 1.73 2.41% |
All data in USD
| Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.27 -8.12% | -0.29 -26.61% | -0.33 -25.54% | 0.05 118.09% | -0.25 7.17% | -0.24 17.69% | -0.22 33.44% | -0.20 -535.37% |
| Revenue Q2Q % growth | -100.00% | 655.177K 2,419.91% | 4.651M 8,059.65% | 3.556M | 5.993M | 8.878M 1,255.05% | 11.922M 156.33% | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -26.559M -8.89% | -27.864M -22.04% | -32.059M -29.31% | -29.539M -20.31% | N/A | N/A | N/A | N/A |
All data in USD
11 analysts have analysed CMRX and the average price target is 8.71 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 8.54.
CHIMERIX INC (CMRX) will report earnings on 2025-05-01, before the market open.
The consensus EPS estimate for the next earnings of CHIMERIX INC (CMRX) is -0.27 USD and the consensus revenue estimate is 0 USD.
The consensus rating for CHIMERIX INC (CMRX) is 76.3636 / 100 . This indicates that analysts generally have a positive outlook on the stock.